Literature DB >> 10477879

Current status of tamoxifen use: An update for the surgical oncologist.

A S Heerdt1, P I Borgen.   

Abstract

The surgical oncologist is frequently responsible for the screening and diagnosis of women with breast cancer. In this pivotal role, they are often the first to discuss treatment options, including nonsurgical interventions, with breast cancer patients. Recent long-term clinical trial data provide support for the use of tamoxifen to prevent breast cancer in women at high risk of the disease. A breast cancer risk assessment can help identify women at higher than average risk for the disease, who may be appropriate candidates for chemoprevention. It is important for the surgical oncologist to understand the current indications and evidence regarding the use of tamoxifen for breast cancer prevention and treatment as they counsel their patients on available options. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477879     DOI: 10.1002/(sici)1096-9098(199909)72:1<42::aid-jso13>3.0.co;2-e

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  TAK-778 induces osteogenesis in ovariectomized rats via an estrogen receptor-dependent pathway.

Authors:  Ming Cai; Yongchun Yu; Shengmei Feng; Kun Tao; Shaohua Li; Lianfu Deng; Zhengdong Cai
Journal:  J Bone Miner Metab       Date:  2010-08-11       Impact factor: 2.626

2.  Estrogen receptor expression and estrogen receptor-independent cytotoxic effects of tamoxifen on malignant rhabdoid tumor cells in vitro.

Authors:  Shigeki Koshida; Tsutomu Narita; Hirofumi Kato; Shinobu Yoshida; Takashi Taga; Shigeru Ohta; Yoshihiro Takeuchi
Journal:  Jpn J Cancer Res       Date:  2002-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.